Metabolomics

Journal Information
ISSN / EISSN : 1573-3882 / 1573-3890
Current Publisher: Springer Science and Business Media LLC (10.1007)
Former Publisher: , Springer Science and Business Media LLC (10.1007) Springer Science and Business Media LLC (10.1007)
Total articles ≅ 1,684
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
LOCKSS
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Metabolomics, Volume 17, pp 1-11; doi:10.1007/s11306-021-01786-3

Abstract:
Background Microorganisms synthesize and release a large diversity of small molecules like volatile compounds, which allow them to relate and interact with their environment. Volatile organic compounds (VOCs) are carbon-based compounds with low molecular weight and generally, high vapor pressure; because of their nature, they spread easily in the environment. Little is known about the role of VOCs in the interaction processes, and less is known about VOCs produced by Malassezia, a genus of yeasts that belongs to the human skin mycobiota. These yeasts have been associated with several dermatological diseases and currently, they are considered as emerging opportunistic yeasts. Research about secondary metabolites of these yeasts is limited. The pathogenic role and the molecular mechanisms involved in the infection processes of this genus are yet to be clarified. VOCs produced by Malassezia yeasts could play an important function in their metabolism; in addition, they might be involved in either beneficial or pathogenic host-interaction processes. Since these yeasts present differences in their nutritional requirements, like lipids to grow, it is possible that these variations of growth requirements also define differences in the volatile organic compounds produced in Malassezia species. Aim of review We present a mini review about VOCs produced by microorganisms and Malassezia species, and hypothesize about their role in its metabolism, which would reveal clues about host-pathogen interaction. Key scientific concepts of review Since living organisms inhabit a similar environment, the interaction processes occur naturally; as a result, a signal and a response from participants of these processes become important in understanding several biological behaviors. The efforts to elucidate how living organisms interact has been studied from several perspectives. An important issue is that VOCs released by the microbiota plays a key role in the setup of relationships between living micro and macro organisms. The challenge is to determine what is the role of these VOCs produced by human microbiota in commensal/pathogenic scenarios, and how these allow understanding the species metabolism. Malassezia is part of the human mycobiota, and it is implicated in commensal and pathogenic processes. It is possible that their VOCs are involved in these behavioral changes, but the knowledge about this remains overlocked. For this reason, VOCs produced by microorganisms and Malassezia spp. and their role in several biological processes are the main topic in this review.
Jing Guo, Jinhui Zhao, Rui Liu, Jiaying Yu, Mingjia Zhang, Hanming Wang,
Metabolomics, Volume 17, pp 1-14; doi:10.1007/s11306-021-01788-1

The publisher has not yet granted permission to display this abstract.
Hunter A. Miller, Ramy Emam, Chip M. Lynch, Samuel Bockhorst,
Metabolomics, Volume 17, pp 1-13; doi:10.1007/s11306-021-01787-2

The publisher has not yet granted permission to display this abstract.
Ho-Jin Kim, Su Jung Kim, Chul-Woong Woo, Sang-Tae Kim, Minju Im, Sun Kyu Park, Jeom-Yong Kim, , ,
Metabolomics, Volume 17, pp 1-13; doi:10.1007/s11306-021-01781-8

The publisher has not yet granted permission to display this abstract.
Correction
Britta Spanier, Anne Laurençon, Anna Weiser, Nathalie Pujol, Shizue Omi, Aiko Barsch, Ansgar Korf, Sven W. Meyer, Jonathan J. Ewbank, Francesca Palladino, et al.
Metabolomics, Volume 17, pp 1-1; doi:10.1007/s11306-021-01784-5

Alexandre Giannecchini Romagnolo,
Metabolomics, Volume 17, pp 1-11; doi:10.1007/s11306-021-01783-6

The publisher has not yet granted permission to display this abstract.
Lucie Lécuyer, Agnès Victor Bala, Aicha Demidem, Adrien Rossary, Nadia Bouchemal, Mohamed Nawfal Triba, Pilar Galan, Serge Hercberg, Valentin Partula, Bernard Srour, et al.
Metabolomics, Volume 17, pp 1-10; doi:10.1007/s11306-021-01780-9

The publisher has not yet granted permission to display this abstract.
Kelli Goodman, Matthew Mitchell, Anne M. Evans, Luke A. D. Miller, Lisa Ford, Bryan Wittmann, Adam D. Kennedy,
Metabolomics, Volume 17, pp 1-11; doi:10.1007/s11306-021-01782-7

The publisher has not yet granted permission to display this abstract.
, Valérie Copié, Brian P. Tripet, Leonardo B. Nogueira, Katiane O. P. C. Nogueira, Krzysztof Ossoliński, Adrian Arendowski, Tomasz Ruman
Metabolomics, Volume 17, pp 1-15; doi:10.1007/s11306-021-01779-2

Abstract:
Introduction Kidney cancer is one of the most frequently diagnosed and the most lethal urinary cancer. Despite advances in treatment, no specific biomarker is currently in use to guide therapeutic interventions. Objectives Major aim of this work was to perform metabolomic and elemental profiling of human kidney cancer and normal tissue and to evaluate cancer biomarkers. Methods Metabolic and elemental profiling of tumor and adjacent normal human kidney tissue from 50 patients with kidney cancer was undertaken using three different analytical methods. Results Five potential tissue biomarkers of kidney cancer were identified and quantified using with high-resolution nuclear magnetic resonance spectroscopy. The contents of selected chemical elements in tissues was analyzed using inductively coupled plasma optical emission spectrometry. Eleven mass spectral features differentiating between kidney cancer and normal tissues were detected using silver-109 nanoparticle enhanced steel target laser desorption/ionization mass spectrometry. Conclusions Our results, derived from the combination of ICP-OES, LDI MS and 1H NMR methods, suggest that tissue biomarkers identified herein appeared to have great potential for use in clinical prognosis and/or diagnosis of kidney cancer.
Back to Top Top